Volume 7.15 | Apr 23

Cord Blood News 7.15 April 23, 2015
Cord Blood News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook   CBN on Twitter
 
TOP STORY
Comparison of Outcomes after Unrelated Cord Blood and Unmanipulated Haploidentical Stem Cell Transplantation in Adults with Acute Leukemia
Investigators compared outcomes after unrelated cord blood transplantation and haploidentical stem cell transplantation in adults with de novo acute myeloid leukemia and acute lymphoblastic leukemia. [Leukemia] Abstract
Enter to Win a Travel Support Award to ISSCR2015!
 
PUBLICATIONS (Ranked by impact factor of the journal)
Molecular and Phenotypic Characterization of CD133 and SSEA4 Enriched Very Small Embryonic-Like Stem Cells in Human Cord Blood
Researchers describe enrichment strategy and molecular and phenotypic characterization of human cord blood embryonic-like stem cells (VSELs). Flow cytometry analysis revealed that majority of VSELs were present in the red blood cells pellet after Ficoll-Hypaque centrifugation in contrast to the hematopoietic stem cells in the interphase layer. [Leukemia] Abstract

Hair Regrowth in Alopecia Areata Patients following Stem Cell Educator Therapy
Scientists developed a stem cell educator therapy in which a patient’s blood is circulated through a closed-loop system that separates mononuclear cells from the whole blood, allowing the cells to briefly interact with adherent human cord blood-derived multipotent stem cells, and returning the “educated” autologous cells to the patient’s circulation. [BMC Med] Abstract | Full Article

Proteomic Analysis of Porcine Mesenchymal Stem Cells Derived from Bone Marrow and Umbilical Cord: Implication of the Proteins Involved in the Higher Migration Capability of Bone Marrow Mesenchymal Stem Cells
Porcine bone marrow mesenchymal stem cells (MSCs) and umbilical cord MSCs were evaluated with flow cytometric and adipogenic and osteogenic differentiation analyses. [Stem Cell Res Ther] Abstract | Full Article

Umbilical Cord Mesenchymal Stem Cells Modulate Dextran Sulphate Sodium Induced Acute Colitis in Immunodeficient Mice
Scientists examined the protective potential of exogenously administered human umbilical cord derived mesenchymal stem cells against dextran sulphate sodium induced acute colitis in immunodeficient NOD.CB17-Prkdc scid/J mice with particular attention to endoplasmic reticulum stress. [Stem Cell Res Ther]
Abstract | Full Article

Role of Hepatocyte Growth Factor in the Immunomodulation Potential of Amniotic Fluid Stem Cells
Researchers found that hepatocyte growth factor produced by human amniotic fluid stem cells exerts a cytoprotective role, inducing an increase in caspase-dependent apoptosis in human immune cells. [Stem Cells Transl Med] Abstract

Human Umbilical Cord-Derived Mesenchymal Stem Cells Improve Learning and Memory Function in Hypoxic-Ischemic Brain-Damaged Rats via an IL-8-Mediated Secretion Mechanism Rather than Differentiation Pattern Induction
Based on flow cytometry analysis, human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) exhibited the morphological characteristics and surface markers of MSCs. All types of hUC-MSCs, including differentiated and redifferentiated cells, promoted learning and memory function recovery in hypoxic-ischemic brain damaged rats. [Cell Physiol Biochem] Full Article

GFP Labeling and Hepatic Differentiation Potential of Human Placenta-Derived Mesenchymal Stem Cells
Scientists established human placenta-derived mesenchymal stem cells (hPMSCs) expressing green fluorescent protein and assayed their hepatic functional differentiation in vitro. The green fluorescent protein (GFP) gene was transduced into hPMSCs using a lentivirus to establish GFP+ hPMSCs. [Cell Physiol Biochem] Full Article

Characteristics of Human Amniotic Fluid Mesenchymal Stem Cells and Their Tropism to Human Ovarian Cancer
Investigators obtained and characterized human amniotic fluid mesenchymal stem cells (AFMSCs) and detected their ovarian cancer tropsim in nude mice model. AFMSCs presented a fibroblastic-like morphology during the culture. [PLoS One] Full Article

Efficacy and Safety of Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells in Anterior Cruciate Ligament Reconstruction of a Rabbit Model: New Strategy to Enhance Tendon Graft Healing
Researchers investigated whether non-autologous transplantation of human umbilical cord blood-derived mesenchymal stem cells could be integrated safely at the bone-tendon junction without immune rejection and could enhance bone-tendon healing effectively during anterior cruciate ligament reconstruction in an animal model. [Arthroscopy] Abstract

Get More of the Cells You Need with StemSpan™ Megakaryocyte Expansion Supplement and StemSpan™ SFEM
 
REVIEWS
Allogeneic Stem Cell Transplantation in Multiple Myeloma: Immunotherapy and New Drugs
The authors examine the current evidence for the use of allogeneic stem cell transplantation in multiple myeloma. They review novel cell therapies that may be exploited to induce myeloma-specific immune responses including the new promising frontier of chimeric antigen receptor-T and -natural killer cells. [Expert Opin Biol Ther] Abstract

Visit our reviews page to see a complete list of reviews in the cord blood research field.

Your Favorite Immunology Newsletters Are Now on Facebook! Like Us Today!
 
INDUSTRY NEWS
Targazyme, Inc. and M.D. Anderson Cancer Center Receive FDA IND Clearance for Phase I/II Study of TZ101-Treated Regulatory T Cells to Prevent Graft vs. Host Disease in Patients Eligible for Hematologic Stem Cell Transplantation
Targazyme Inc. announced that the U.S. Food and Drug Administration (FDA) has granted IND Clearance to M.D. Anderson Cancer Center to start enrolling patients in a Phase I/II clinical study to evaluate the safety and efficacy of TZ101-fucosylated regulatory T cells in preventing and reducing the severity and incidence of graft vs. host disease in patients eligible for hematologic stem cell transplant. [Targazyme Inc.] Press Release

Actinium Doses the First Patient in the Fourth, Final Cohort of Its Actimab-A Trial
Actinium Pharmaceuticals, Inc. announced that the first patient was successfully treated with Actimab-A drug candidate in the fourth and last cohort of the ongoing Phase I/II trial of Actimab-A. Actimab-A is being developed for newly diagnosed AML patients over the age of 60 ineligible for standard induction chemotherapy. [Actinium Pharmaceuticals, Inc.] Press Release

From our sponsor: Studying ESCs or iPSCs? Request your free copy of the small molecules wallchart.
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW Stem Cells & Regenerative Medicine Congress USA
September 2-3, 2015
Washington D.C., United States

Visit our events page to see a complete list of events in the cord blood community.
 
JOB OPPORTUNITIES
NEW Postdoctoral Associate – Epigenetic Regulation of Normal and Leukemic Stem Cells (Sanford-Burnham Medical Research Institute)

Principal Scientist – Hematopoietic Products (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Postdoctoral Fellow – Stem Cell Trans Regulation (BloodCenter of Wisconsin)

Postdoctoral Fellow – Hematopoietic Stem Cell Biology (University of Leuven)

Postdoctoral Fellow – Hematopoietic Stem Cell Research (Lund University)

Postdoctoral Research Fellow – Stem Cell/Hematopoiesis Research (BloodCenter of Wisconsin)

Research Associate – Hematopoietic and Leukemic Stem Cells (Shanghai Jiao-Tong University School of Medicine)

Postdoctoral Fellows – Leukemia Research and Stem Cell Biology (Josep Carreras Leukemia Research Institute)

PhD Studentships – Expansion of Umbilical Cord Blood Stem Cells (University College London)

Cord Tissue Processing Technician (Cord Blood Registry)


Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Cord Blood News: Archives | Events | Contact Us